Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from...
Publisher
France
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Innate Pharma (IR)
- Region
- France
- Scope
- Industry
- Published
- July 21, 2026
- Language
- EN
Topics
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from...
Source route
Continue on innate-pharma.com
Leave the platform to read the original full article on the publisher site.
Source: Innate Pharma (IR)
Scope: Industry
Related coverage